A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines
Advanced Science · 2026-02 · 13 (8)
DOI: 10.1002/advs.202512535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 21.11.2025. Verfasst von Qimeng Yin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Human Phenome Institute, Fudan University, Shanghai, 201203, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Spleen, RNA, Messenger, Lipids. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Shanghai Pilot Program for Basic Research-Fudan University, Innovation Cooperation Project of the Greater Bay Area Institute of Precision Medicine.
Abstract (Originalsprache)
mRNA vaccines offer great potential for cancer immunotherapy, yet efficient delivery of antigen‐encoding mRNA to antigen‐presenting cells (APCs) in lymphoid organs remains a significant challenge. Here, OncoLRC is introduced, a rationally engineered, spleen‐tropic, one‐component lipid‐mRNA complex that selectively delivers mRNA to splenic APCs following systemic administration. Through a systemic screening and optimization process, a dimethylamino (DMA)‐lipidoid‐based OncoLRC formulation that achieves nearly exclusive spleen‐targeting mRNA delivery, outperforming its conventional four‐component lipid nanoparticle (LNP) formulation counterpart has been developed. Notably, OncoLRC requires a reduced lipid‐to‐mRNA weight ratio of 1.5:1 compared to the typical 10:1 ratio in standard LNPs. OncoLRC formulated with ovalbumin (OVA) mRNA (OncoLRC OVA ) promotes dendritic cell (DC) maturation and activation, eliciting robust antigen‐specific immune responses. Mechanistic studies suggest that splenic delivery is mediated primarily via macropinocytosis. Moreover, OncoLRC OVA enhances the secretion of endogenous cytokines such as IL‐12, further stimulating T cell activation and cytotoxic activity. In the B16F10‐OVA cold tumor model, OncoLRC OVA demonstrates strong prophylactic antitumor efficacy and exhibits a profound synergistic effect when combined with immune checkpoint blockade therapy, leading to significant tumor growth inhibition. Collectively, our findings establish OncoLRC as a simple yet effective APC‐targeted mRNA delivery platform, highlighting its potential as a next‐generation mRNA cancer vaccine system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Phenome Institute, Fudan University, Shanghai, 201203, China.
- Center for mRNA Translational Research, Fudan University, Shanghai, 200438, China.
- Zhangjiang mRNA Innovation and Translation Center, Shanghai, 201203, China.
ORCID-Profile: Min Qiu
Förderung
- National Key Research and Development Program of China
- Shanghai Pilot Program for Basic Research-Fudan University
- Innovation Cooperation Project of the Greater Bay Area Institute of Precision Medicine
- Fudan University startup fund
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
- National Natural Science Foundation of China
Zitieren
APA
Yin, Q., Zhang, C., Li, J., Huang, K., & Qiu, M. (2026). A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines. Advanced Science, 13(8). https://doi.org/10.1002/advs.202512535
Vancouver
Yin Q, Zhang C, Li J, Huang K, Qiu M. A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines. Advanced Science. 2026;13(8). doi:10.1002/advs.202512535
BibTeX
@article{Yin2026,
author = {Yin, Qimeng and Zhang, Chenchen and Li, Jiahao and Huang, Kun and Qiu, Min},
title = {A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {8},
doi = {10.1002/advs.202512535}
}
EUVIMED